Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712720 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
A Phase 2 study, sponsored by Rezolute.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT05712720 is a Phase 2 study that has completed, run by Rezolute. The registered enrollment target is 94 participants.
The verdict
NCT05712720, a Phase 2 study, has completed, sponsored by Rezolute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
Interventions
- DRUG Experimental: Group 1 - 50mg RZ402
- DRUG Experimental: Group 2 - 200mg RZ402
- DRUG Experimental: Group 3 - 400mg RZ402
- OTHER Placebo: Group 4 - Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712720
The ClinicalTrials.gov registry entry for NCT05712720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rezolute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Experimental: Group 1 - 50mg RZ402 is the first listed.
NCT05712720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05712720 about?
NCT05712720 is a clinical study titled "Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)". The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
What is the current status of trial NCT05712720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2023-02-06. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05712720?
The interventions under investigation include: Experimental: Group 1 - 50mg RZ402 (DRUG), Experimental: Group 2 - 200mg RZ402 (DRUG), Experimental: Group 3 - 400mg RZ402 (DRUG), Placebo: Group 4 - Placebo (OTHER).
Who is sponsoring clinical trial NCT05712720?
This trial is sponsored by Rezolute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.